Tobacco-derived compound prevents memory loss in Alzheimer’s
April 28th, 2011 - 2:17 pm ICT by ANIWashington, April 28 (ANI): A study led by researchers at Bay Pines VA Healthcare System and the University of South Florida has found that Cotinine, a compound derived from tobacco, reduced plaques associated with dementia and prevented memory loss in a mouse model of Alzheimer’s disease.
“We found a compound that protects neurons, prevents the progression of Alzheimer’s disease pathology, enhances memory and has been shown to be safe,” said Valentina Echeverria, a scientist at Bay Pines VA Healthcare System and an assistant professor of Molecular Medicine at USF Health.
“It looks like cotinine acts on several aspects of Alzheimer’s pathology in the mouse model. That, combined with the drug’s good safety profile in humans, makes it a very attractive potential therapy for Alzheimer’s disease,” she added.
The Bay Pines VA/USF team decided to look at the effects of cotinine, the major byproduct of nicotine metabolism, in Alzheimer’s disease mice. Cotinine is nontoxic and longer lasting than nicotine. Furthermore, its safety has already been demonstrated in human trials evaluating cotinine’s potential to relieve tobacco withdrawal symptoms.
The brains of Alzheimer’s mice treated with cotinine showed a 26-percent reduction in deposits of amyloid plaques, which are a hallmark of Alzheimer’s disease. Cotinine also inhibited the accumulation of the amyloid peptide oligomers - a predecessor of senile plaques - in the brains of these mice. Furthermore, the researchers discovered that cotinine stimulated the signaling factor Akt, which promotes the survival of neurons and enhances attention and memory.
Senile plaques likely had not yet formed or were just beginning to accumulate in the brains of the young adult mice when long-term cotinine treatment was started. The researchers suggested “cotinine may be useful in preventing cognitive deterioration when administered to individuals not yet exhibiting Alzheimer’s disease cognitive impairment or those with mild cognitive impairment at early stages of the disease.”
The finding is detailed in the Journal of Alzheimer’s Disease. (ANI)
- Drug reverses Alzheimer's symptoms in mice: Study - Feb 10, 2012
- Scientists reverse loss of smell in early Alzheimer's - Dec 01, 2011
- Cellphone use can protect against Alzheimer's disease - Jan 07, 2010
- Rheumatoid arthritis may protect against Alzheimer's disease - Aug 23, 2010
- Novel gene therapy shows promise against Alzheimer's - Mar 05, 2011
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- Indications of Alzheimer's may be evident decades before first signs - Mar 29, 2011
- Drug reversing Alzheimer's symptoms found - Feb 12, 2012
- The real culprit behind Alzheimer's disease - Apr 28, 2010
- New finding shows promise in the fight against Alzheimer's - Jan 27, 2011
- Chronic high cholesterol diet leads to brain damage: Study - Nov 25, 2010
- Asthma drug could help fight Alzheimer's - Mar 27, 2011
- Asthma drug could help fight Alzheimer's disease - Mar 26, 2011
- Blood vessel dysfunction linked to heart disease also plays role in Alzheimer's - Dec 03, 2010
- New gene therapy may 'fix memory problems in Alzheimer patients' - Nov 29, 2010
Tags: adult mice, amyloid plaques, bay pines, byproduct, cognitive deterioration, disease pathology, healthcare system, impair, memory loss, molecular medicine, mouse model, nicotine, nicotine metabolism, peptide, safety profile, senile plaques, tobacco withdrawal, university of south florida, withdrawal symptoms, young adult